Abstract
Epigenetic DNA modification by aberrant methylation of cytosine residues is thought to be an important mechanism contributing to tumorigenesis. Methylation of cytosines normally occurs at distinct sites of the genome containing stretches of repeated CpG (CpG islands) often found within promoter areas of transcribed genes. The cytosine methylation pattern is established very early in development by a continuous process of demethylation and de novo methylation (for review see refs. 1,2). Normally, methylation patterns are faithfully maintained through all subsequent cell divisions and are dependent on DNA methyltransferase activity (3). It has been observed, however, that tumour cells often show extensive upregulation of DNA methyltransferase and at the same time hypomethylation of CpG sites (4). The mechanism of this apparent deregulation in cancer cells is not clear but is generally thought that de novo methylation of otherwise nonmethylated genes is the active component of functional disturbance in cancer (4-6). Methylated islands will recruit special methyl-binding proteins and in conjunction with histone deacetylases are then thought to form repressive chromatin states around the promoter regions, leading to transcriptional loss of genes residing downstream (7). If important genes reside within this region loss of functional control in cell proliferation will ensue. It is therefore not surprising that de novo methylation found in cancer includes many tumor-suppressor genes known to date, thus forming an alternative to gene silencing by inactivating deletions (8).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bird, A. P. (1986) CpG-rich islands and the function of DNA methylation. Nature 321, 209ā213.
Turker, M. S. and Bestor, T. H. (1997) Formation of methylation patterns in the mammalian genome. Mutat. Res. 386, 119ā130.
Holliday, R. (1990) DNA methylation and epigenetic inheritance. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 326, 329ā338.
Schmutte, C. and Fishel, R. (1999) Genomic instability: first step to carcinogenesis. Anticancer Res. 19, 4665ā4696.
Baylin, S. B., Esteller, M., Rountree, M. R., Bachman, K. E., Schuebel, K., and Herman, J. G. (2001) Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum. Mol. Genet. 10, 687ā692.
Issa, J. P. (2000) CpG-island methylation in aging and cancer. Curr. Top. Microbiol. Immunol. 249, 101ā118.
Rountree, M. R., Bachman, K. E., Herman, J. G., and Baylin, S. B. (2001) DNA methylation, chromatin inheritance, and cancer. Oncogene 20, 3156ā3165.
Baylin, S. B., Herman, J. G., Graff, J. R., Vertino, P. M., and Issa, J. P. (1998) Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res. 72, 141ā196.
Gazdar, A. F. (1994) The molecular and cellular basis of human lung cancer. Anticancer. Res. 14, 261ā267.
Fontanini, G., Vignati, S., Bigini, D., Merlo, G. R., Ribecchini, A., Angeletti, C. A., et al. (1994) Human non-small cell lung cancer: p53 protein accumulation is an early event and persists during metastatic progression. J. Pathol. 174, 23ā31.
Sozzi, G., Miozzo, M., Donghi, R., Pilotti, S., Cariani, C. T., Pastorino, U., et al. (1992) Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res. 52, 6079ā6082.
Walker, C., Robertson, L. J., Myskow, M. W., Pendleton, N., and Dixon, G. R. (1994) p53 expression in normal and dysplastic bronchial epithelium and in lung carcinomas. Br. J. Cancer 70, 297ā303.
Tockman, M. S. (2000) Advances in sputum analysis for screening and early detection of lung cancer. Cancer Control 7, 19ā24.
Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., et al. (1995) 5ā² CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1, 686ā692.
Shapiro, G. I., Park, J. E., Edwards, C. D., Mao, L., Merlo, A., Sidransky, D., et al. (1995) Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines. Cancer Res. 55, 6200ā6209.
Ahrendt, S. A., Chow, J. T., Xu, L. H., Yang, S. C., Eisenberger, C. F., Esteller, M., et al. (1999) Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J. Natl. Cancer Inst. 91, 332ā339.
Belinsky, S. A., Nikula, K. J., Palmisano, W. A., Michels, R., Saccomanno, G., Gabrielson, E., et al. (1998) Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl. Acad. Sci. USA 95, 11891ā11896.
Issa, J. P., Baylin, S. B., and Belinsky, S. A. (1996) Methylation of the estrogen receptor CpG island in lung tumors is related to the specific type of carcinogen exposure. Cancer Res. 56, 3655ā3658.
Eguchi, K., Kanai, Y., Kobayashi, K., and Hirohashi, S. (1997) DNA hypermeth-ylation at the D17S5 locus in non-small cell lung cancers: its association with smoking history. Cancer Res. 57, 4913ā4915.
Sato, M., Mori, Y., Sakurada, A., Fujimura, S., and Horii, A. (1998) The H-cadherin (CDH13) gene is inactivated in human lung cancer. Hum. Genet. 103, 96ā101.
Esteller, M., Sanchez-Cespedes, M., Rosell, R., Sidransky, D., Baylin, S. B., and Herman, J. G. (1999) Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59, 67ā70.
Tang, X., Khuri, F. R., Lee, J. J., Kemp, B. L., Liu, D., Hong, W. K., and Mao, L. (2000) Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J. Natl. Cancer Inst. 92, 1511ā1566.
Virmani, A. K., Rathi, A., Zochbauer-Muller, S., Sacchi, N., Fukuyama, Y., Bryant, D., et al. (2000) Promoter methylation and silencing of the retinoic acid receptorbeta gene in lung carcinomas. J. Natl. Cancer Inst. 92, 1303ā1307.
Zochbauer-Muller, S., Fong, K. M., Virmani, A. K., Geradts, J., Gazdar, A. F., and Minna, J. D. (2001) Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 61, 249ā255.
Tockman, M. S. and Mulshine, J. L. (2000) The early detection of occult lung cancer. Chest Surg. Clin. North Am. 10, 737ā749.
Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., and Baylin, S. B. (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA 93, 9821ā9826.
Kersting, M., Friedl, C., Kraus, A., Behn, M., Pankow, W., and Schuermann, M. (2000) Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J. Clin. Oncol. 18, 3221ā3229.
Frommer, M., McDonald, L. E., Millar, D. S., Collis, C. M., Watt, F., Grigg, G. W., et al. (1992) A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl. Acad. Sci. USA 89, 1827ā1831.
Stƶger, R., Kajimura, T. M., Brown, W. T., and Laird, C. D. (1997) Epigenetic variation illustrated by DNA methylation patterns of the fragile-X gene FMR1. Hum. Mol. Genet. 6, 1791ā1801.
Zhang, L., Cui, X., Schmitt, K., Navidi, W., and Arnheim, N. (1992) Whole genome amplification from a single cell: implications for genetic analysis. Proc. Natl. Acad. Sci. USA 89, 5847ā5851.
Palmisano, W. A., Divine, K. K., Saccomanno, G., Gilliland, F. D., Baylin, S. B., Herman, J. G., and Belinsky, S. A. (2000) Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 60, 5954ā5958.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
Ā© 2003 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Schuermann, M., Kersting, M. (2003). Sensitive Detection of Hypermethylated p16INK4a Alleles in Exfoliative Tissue Material. In: Driscoll, B. (eds) Lung Cancer. Methods in Molecular Medicineā¢, vol 74. Humana Press, Totowa, NJ. https://doi.org/10.1385/1-59259-323-2:101
Download citation
DOI: https://doi.org/10.1385/1-59259-323-2:101
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-0-89603-985-8
Online ISBN: 978-1-59259-323-1
eBook Packages: Springer Protocols